Difference between revisions of "Increasing Competitiveness through innovation in biotechnology"

From ScenarioThinking
Jump to navigation Jump to search
(rPbhsWpP)
 
(215 intermediate revisions by more than 100 users not shown)
Line 1: Line 1:
'''This page is under construction and edited by Murat Akguc EMBA09. In case of any questions/remarks, feel free to [mailto:murat.akguc@gmail.com contact me]'''
ScjnDJ http://angloman.com/ Xanax online http://bsgkt.com/ Buy Ambien http://www.celticamarillo.org/ Cialis http://www.alaskaemedia.com/ Viagra
 
==Description:==
As companies face pressure from increased competition, shortening product life cycles and
growing product complexity many are finding they need to change the way they develop new
technologies, products and services.
 
Biotechnology is of growing importance to pharmaceutical research. An increasing number of innovative medicines have their origin in biotechnological research, i.e. the use of living organisms or their derivatives for therapeutic purposes, rather than chemical substances as in modern pharmacological treatment. As these products are extremely complicated and expensive to develop and test, it is necessary create an environment that rewards innovation and removes unnecessary regulatory, administrative or economic obstacles.
 
Biotechnology has become the driving force of radical changes in innovation
processes in various sectors. This is best illustrated by the pharmaceutical industry where
the traditional chemical paradigm of drug discovery and development is being replaced
by a new biotechnological paradigm. This has important consequences for the structure
and functioning of the biopharmaceutical innovation system: biotechnology firms and
public sector research organisations are becoming key actors generating new knowledge,
tools and substances for the pharmaceutical industry. Regulations, standards and
intellectual property rights (IPR) schemes have to deal with new types of components,
and, on the demand side, new solutions are emerging for as yet unmet needs.
 
==Enablers:==
*  [[Unification of regulatory approval]]
*  [[Continuously growing demand for new medical applications]]
*  [[Aging population]]
*  [[THE POTENTIAL OF NANOTECHNOLOGY]]
 
==Inhibitors:==
Factors which weaken this driving force. (these are actually other driving forces, and you can link to them in the wiki!)
==Paradigms:==
Changes in ways of thinking about the world due to the driving force.
==Experts:==
Sources for additional information about this driving force. (if you have found people, put the links to them)
==Timing:==
Dates for key milestones in the development of the driving force.
==Web Resources:==
 
*    Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level, OECD, 2006 (http://www.oecd.org/document/55/0,3343,en_2649_34273_36446711_1_1_1_1,00.html)
 
*    Sustaining Competitiveness through Alliances and Innovation: The impact of Alliance Management Issues on learning skills and competencies from partner(s), Prof. S. Raghunath ([mailto:srnath@iimb.ernet.in Email]), Thomas Joseph ([mailto:thomasj03@iimb.ernet.in Email]), (http://dspace.iimk.ac.in/bitstream/2259/492/1/349-358+.pdf)
 
*    European Commission - Enterprise and Industry Directorate General - Consumer goods - (http://ec.europa.eu/enterprise/phabiocom/index_en.htm)

Latest revision as of 14:47, 2 June 2010

ScjnDJ http://angloman.com/ Xanax online http://bsgkt.com/ Buy Ambien http://www.celticamarillo.org/ Cialis http://www.alaskaemedia.com/ Viagra

Retrieved from "https://www.scenariothinking.org/index.php?title=Increasing_Competitiveness_through_innovation_in_biotechnology&oldid=167866"